Você procurou por: blepharospasm (Inglês - Maltês)

blepharospasm, (mrz 60201-0003)
botox (n=155)

visual acuity reduced blepharospasm
tnaqqis fl-akutezza viżwali blefarospażmu

blepharospasm, retinal haemorrhage, uveitis.
blefarospażmu, emorraġija retinali, uveite.

blepharospasm the following adverse reactions were reported with xeomin:
blefarospażmu dawn ir- reazzjonijiet avversi li ġejjin kienu rrappurtati bi xeomin:

oculogyric crises, activation of latent horner's syndrome, blepharospasm
kriżijiet okulogiriċi, attivazzjoni tas- sindromu moħbi ta’ horner, blefarospażmu

eyelash darkening, blepharospasm, retinal haemorrhage, uveitis, periorbital erythema.
ix-xagħar tal-għajnejn jiskura, blefarospażmu, emorraġija retinali, uveite, eritema madwar l- għajnejn.

muscle twitching and blepharospasm may be taken as early signs to consider levodopa dosage reduction.
kontrazzjonijiet mhux volontarji tal - muskoli u blefarospażmu jistgħu jitqiesu bħala sinjali bikrija biex tiġi kkunsidrata tnaqqis fid- doża ta ’ levodopa.

retinal haemorrhage, uveitis, cystoid macular oedema, iritis, blepharospasm, eyelid retraction
emorraġija fir-retina, uveite, edima makulari ċistojde, irite, blefarospażmu, ritrattazzjoni ta’ tebqet il-għajn

4.6% for botox in the blepharospasm phase iii study) and occurred in bps patients only.
4. 6% għal botox fl- istudju ta ’ blefarospażmu ta ’ fażi iii) u seħħ f’ pazjenti b’ bps biss.

retinal haemorrhage, uveitis, cystoid macular oedema, iritis, blepharospasm, eyelid retraction, periorbital erythema
emorraġija fir-retina, uveite, edema makulari ċistojde, irite, blefarospażmu, ritrattazzjoni ta’ tebqet il-għajn, eritema periorbitali

eyelid spasm (blepharospasm) usually, the first onset of effect is observed within four days after injection.
spażmu ta ’ tebqet il- għajn (blefarospażmu) normalment, l- ewwel l- bidu ta ’ l- effett ikun osservat fi żmien erbat ijiem wara l- injezzjoni.

blepharospasm because of the anticholinergic effect of botulinum neurotoxin type a, xeomin should be used with caution in patients at risk of developing an angle closure glaucoma.
blefarospażmu minħabba l- effett antikolinerġiku ta ’ botulinum newrotossina ta ’ tip a, xeomin għandu jintuża bl- attenzjoni f’ pazjenti b’ riskju li jiżviluppaw glawkoma tat- tip angle closure.

xeomin is indicated for the symptomatic management of blepharospasm and cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adults.
xeomin hu indikat għall- immaniġġjar sintomatiku ta ’ blefarospażmu u distonja fil- għonq ta ’ forma fil- biċċa l- kbira tagħha rotazzjonali (torticollis spażmodika) fl- adulti.

eyelid spasm (blepharospasm) please inform your doctor prior to any treatment, if you: • have had an eye surgery.
spażmu ta ’ tebqet il- għajn (blefarospażmu) jekk jogħġbok informa lit- tabib tiegħek qabel kwalunkwe kura, jekk inti: • kellek operazzjoni f’ għajnejk.

dry eye, eye pain, visual acuity reduced, visual impairment, blepharospasm (abnormal, involuntary blinking or spasm of the eyelids).
għajn xotta, uġigħ fl-għajnejn, akutezza viżiva mnaqqsa, indeboliment viżiv, blefarospażmu (teptip jew spażmu tal-kpiepel tal-għajnejn b’mod mhux normali u involontarju).

in the phase iii study mrz-0003 in patients with blepharospasm, no patient in both treatment groups had a hda antibody titer higher than 1 mu/ l at baseline or at final visit.
fl- istudju tat- tielet fażi mrz- 0003 bis- sehem ta ’ pazjenti bi blefarospażmu, l- ebda pazjent miż- żewġ gruppi ma kellu livell ta ’ antikorpi ta ’ l- hda ogħla minn 1 mu/ l fl- analiżi inizjali jew fl- aħħar żjara.

the submitted clinical trial programme consisted of: • two phase i studies mrz/ btc-9901 and mrz/ btc-0113, of which the latter was performed after completion of the phase iii studies • one phase ii study (mrz/ btc-9801) • two phase iii studies (one study in each of the intended indication, spasmodic torticollis (mrz/ btc-0013) and blepharospasm (mrz/ btc-0003) respectively)
il- programm ta ’ l- istudju kliniku sottomess kien jikkonsisti minn: • Żewġ studji ta ’ l- ewwel fażi mrz/ btc- 9901 u mrz/ btc- 0113, li minnhom it- tieni wieħed sar wara t- tlestija ta ’ l- istudji tat- tielet fażi • studju wieħed tat- tieni fażi (mrz/ btc- 9801) • Żewġ studji tat- tielet fażi (studju wieħed f’ kull waħda mill- indikazzjonijiet intiżi, torticollis spasmodika (mrz/ btc- 0013) u blefarospażmu (mrz/ btc- 0003) rispettivament)